Report cover image

North America Therapeutic Vaccines Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

Publisher The Insight Partners
Published Sep 01, 2025
Length 121 Pages
SKU # TIP20577489

Description

The North America therapeutic vaccines market is projected to grow significantly, reaching approximately USD 1,360,744.52 thousand by 2031, up from USD 565,764.46 thousand in 2024, reflecting a compound annual growth rate (CAGR) of 13.4% from 2024 to 2031.

Executive Summary and Market Analysis

The therapeutic vaccines market in North America is divided into three main regions: the United States, Canada, and Mexico. The U.S. is expected to be a key driver of market growth due to several factors, including the rising incidence of cancer, increased investment in research and development, and a notable rise in product launches. Additionally, strategic initiatives such as the introduction of new products, regulatory approvals, partnerships, and acquisitions are further enhancing the growth of the therapeutic vaccine market in this region.

Market Segmentation Analysis

The therapeutic vaccines market can be analyzed through various segments, including product type, technology, and end user.

By Product: The market is categorized into cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
By Technology: The market is divided into allogenic and autologous vaccines, where allogenic vaccines are expected to dominate the market share in 2024.
By End User: The end-user segment includes hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

The prevalence of chronic conditions such as cancer, neurological disorders, and autoimmune diseases is on the rise globally, driven by factors like aging populations, lifestyle changes, and environmental influences. According to the World Health Organization (WHO), noncommunicable diseases lead to 41 million deaths annually, representing 74% of total mortality. In 2022, around 20 million new cancer cases were diagnosed, with approximately 9.7 million deaths attributed to the disease. Furthermore, a study published in The Lancet Neurology in April 2024 indicated that over 3 billion people, or 43% of the global population, were living with neurological conditions as of 2021. Autoimmune diseases affect 5-10% of the population in industrialized nations, impacting around 50 million Americans. The WHO also reported that over 1.8 million people worldwide suffered from multiple sclerosis as of August 2023.

These alarming statistics underscore the urgent need for innovative therapeutic solutions. Therapeutic vaccines are designed to treat existing diseases rather than prevent them, aiming to activate the immune system to target specific diseases. For instance, the Sipuleucel-T (Provenge) vaccine has shown promise in improving survival rates for prostate cancer patients. As the demand for innovative treatments for chronic diseases rises, therapeutic vaccines are positioned to provide new avenues for long-term disease management and enhanced patient outcomes.

Country Insights

The North American therapeutic vaccines market is primarily composed of the U.S., Canada, and Mexico, with the U.S. holding the largest market share in 2024. The growth of the therapeutic vaccines market in the U.S. is fueled by the increasing prevalence of chronic diseases, including cancer and infectious diseases. The American Cancer Society reported that in 2022, over 1.9 million new cancer cases were diagnosed, resulting in approximately 610,000 deaths. In 2024, the number of cancer diagnoses in the U.S. is expected to reach 2 million. This surge in cancer cases is driving the demand for innovative treatment options, with therapeutic vaccines offering promising alternatives to traditional therapies. Provenge, the first FDA-approved therapeutic cancer vaccine for prostate cancer, exemplifies the potential of immunotherapies to extend patient survival. The rising incidence of cancer is prompting increased investment in research and development and fostering collaborations between companies and academic institutions.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon, among others. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase their market presence.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Therapeutics Vaccine Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the North America Therapeutics Vaccine Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America Therapeutics vaccine Market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

Table of Contents

121 Pages
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. North America Therapeutic Vaccines Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic Conditions
4.1.2 Increasing Investments and Funding for Vaccine Development
4.2 Market Restraints
4.2.1 Regulatory Challenges
4.3 Market Opportunities
4.3.1 Extending Product Pipeline
4.4 Future Trends
4.4.1 Advancements in Vaccine Technology
4.5 Impact of Drivers and Restraints:
5. Therapeutic Vaccines Market - North America Market Analysis
5.1 North America Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
5.2 North America Therapeutic Vaccines Market Forecast Analysis
6. North America Therapeutic Vaccines Market Analysis - by Product
6.1 Cancer Vaccine
6.1.1 Overview
6.1.2 Cancer Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.2 Infectious Disease Vaccine
6.2.1 Overview
6.2.2 infectious Disease Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.3 Others
6.3.1 Overview
6.3.2 Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7. North America Therapeutic Vaccines Market Analysis - by Technology
7.1 Allogenic Vaccine
7.1.1 Overview
7.1.2 Allogenic Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Autologous Vaccine
7.2.1 Overview
7.2.2 Autologous Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8. North America Therapeutic Vaccines Market Analysis - by End User
8.1 Hospitals
8.1.1 Overview
8.1.2 Hospitals: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.2 Clinics
8.2.1 Overview
8.2.2 Clinics: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.3 Others
8.3.1 Overview
8.3.2 Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9. North America Therapeutic Vaccines Market - Country Analysis
9.1 North America
9.1.1 North America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
9.1.1.1 North America Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
9.1.1.2 United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.2.1 United States: North America Therapeutic Vaccines Market Share - by Product
9.1.1.2.2 United States: North America Therapeutic Vaccines Market Share - by Technology
9.1.1.2.3 United States: North America Therapeutic Vaccines Market Share - by End User
9.1.1.3 Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.3.1 Canada: North America Therapeutic Vaccines Market Share - by Product
9.1.1.3.2 Canada: North America Therapeutic Vaccines Market Share - by Technology
9.1.1.3.3 Canada: North America Therapeutic Vaccines Market Share - by End User
9.1.1.4 Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.4.1 Mexico: North America Therapeutic Vaccines Market Share - by Product
9.1.1.4.2 Mexico: North America Therapeutic Vaccines Market Share - by Technology
9.1.1.4.3 Mexico: North America Therapeutic Vaccines Market Share - by End User
10. Therapeutic Vaccines Market - Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Therapeutic Vaccines Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Dendreon
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 BioNTech SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Serum Institute of India Pvt. Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Merck & Co Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Amgen Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 ISA Pharmaceuticals BV
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 INOVIO Pharmaceuticals Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Transgene SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 THERAVECTYS SA
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 CureVac SE
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
List of Tables
Table 1. North America Therapeutic Vaccines Market Segmentation
Table 2. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Table 3. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Product
Table 4. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Technology
Table 5. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
Table 6. North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
Table 7. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 8. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 9. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 10. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 11. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 12. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 13. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 14. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 15. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 16. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
Table 17. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
Table 18. Glossary of Terms, Therapeutic Vaccines Market
 
List of Figures
Figure 1. North America Therapeutic Vaccines Market Segmentation - Country
Figure 2. North America Therapeutic Vaccines Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
Figure 5. North America Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
Figure 6. Cancer Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 7. infectious Disease Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 8. Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 9. North America Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
Figure 10. Allogenic Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 11. Autologous Vaccine: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 12. North America Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
Figure 13. Hospitals: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 14. Clinics: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 15. Others: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 16. North America Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 17. United States: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 18. Canada: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 19. Mexico: North America Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 20. Growth Strategies in the Therapeutic Vaccines Market
 

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us